BENGALURU (Reuters) - Mylan NV MYL.O said on Monday it would launch a generic version of Gilead Sciences Inc's GILD.O COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.
California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries.
Last month, two Indian drugmakers, Cipla Ltd CIPL.NS and privately-held Hetero Labs Ltd, also launched generic versions of the treatment. Cipla will price its version, Cipremi, at less than 5,000 rupees, while Hetero has priced Covifor at 5,400 rupees.
Gilead, last week, priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
Mylan’s price was for 100 mg vials, but it was not immediately clear how many of those vials would be required for a full treatment course. Gilead has said for a five-day treatment course, a patient would need six vials of remdesivir.
Remdesivir is in high demand after the intravenously-administered medicine helped to shorten hospital recovery times in a clinical trial but there has been concerns over its supply.
Mylan said it would manufacture remdesivir in India at its injectables facilities and was working toward expanding access for patients in the 127 low- and middle-income countries where it is licensed by Gilead Sciences to do so.
The Drug Controller General of India (DCGI) approved Mylan’s remdesivir version, to be called Desrem, for the treatment of suspected or laboratory confirmed severe incidences of COVID-19 in adults and children, the company said in a statement.
India is the world’s third worst hit nation, with the number of coronavirus cases surging to 697,413 on Monday.
Reporting by Anuron Kumar Mitra and Ankur Banerjee in Bengaluru; Editing by Rashmi Aich and Sweta Singh
Our Standards: The Thomson Reuters Trust Principles.